Patient Experiences with Tadalafil for Sexual Wellness

Any clinically significant difference in effect will need to be clarified by post-marketing surveillance of vardenafil and tadalafil.2,12 While sildenafil and vardenafil have similar recommended dosing, the dosing schedule for tadalafil may differ due to its greater time to maximum concentration and longer half-life. Dosing guidelines are listed in Table 2.2,13 The PDE-5 inhibitors are not FDA-approved for use in women or children. All of these agents are classified as pregnancy-risk category B.8-10 Pregnancy category B is defined as either animal-reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the first trimester (and there is no evidence of a risk in later trimesters).21 The price of sildenafil 25- or 50-mg tablets is $90.99 for ten tablets or $259.97 for 30 tablets, while the 100 mg strength of sildenafil is $93.99 for ten tablets or $267.97 for 30 tablets. Finally, the price of tadalafil 5-, 10-, or 20-mg tablets is $89.99 for ten tablets or $259.97 for 30 tablets.22-24 Recently, sildenafil has been investigated for the treatment of pulmonary hypertension.25 It has been shown to decrease pulmonary artery pressure and pulmonary vascular resistance, decrease symptoms, and improve New York Heart Association functional class in patients with pulmonary hypertension.

Dosing, Safety, and Guidance

Any clinically significant difference in effect will need to be clarified by post-marketing surveillance of vardenafil and tadalafil.2,12 While sildenafil and vardenafil have similar recommended dosing, the dosing schedule for tadalafil may differ due to its greater time to maximum concentration and longer half-life. Dosing guidelines are listed in Table 2.2,13 The PDE-5 inhibitors are not FDA-approved for use in women or children. All of these agents are classified as pregnancy-risk category B.8-10 Pregnancy category B is defined as either animal-reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the first trimester (and there is no evidence of a risk in later trimesters).21 The price of sildenafil 25- or 50-mg tablets is $90.99 for ten tablets or $259.97 for 30 tablets, while the 100 mg strength of sildenafil is $93.99 for ten tablets or $267.97 for 30 tablets. Finally, the price of tadalafil 5-, 10-, or 20-mg tablets is $89.99 for ten tablets or $259.97 for 30 tablets.22-24 Recently, sildenafil has been investigated for the treatment of pulmonary hypertension.25 It has been shown to decrease pulmonary artery pressure and pulmonary vascular resistance, decrease symptoms, and improve New York Heart Association functional class in patients with pulmonary hypertension. No trials assessing the ability of vardenafil or tadalafil to treat pulmonary hypertension have been reported.

Missed Dose

The place of sildenafil and the other PDE-5 inhibitors in treating pulmonary hypertension remains to be elucidated. Researchers have also studied sildenafil for the treatment of sexual dysfunction in women.26,27 While sil-denafil is currently not FDA-approved for this indication, clinical trials have shown improvement of sexual function for some women. Additional studies are necessary to establish clinical efficacy in a larger patient population and to define which female patients may receive benefit from treatment with sildenafil. Sildenafil, vardenafil, and tadalafil are all effective treatments for ED by inhibiting PDE-5. Some differences exist that may clinically differentiate these agents. No trials assessing the ability of vardenafil or tadalafil to treat pulmonary hypertension have been reported. The place of sildenafil and the other PDE-5 inhibitors in treating pulmonary hypertension remains to be elucidated. Researchers have also studied sildenafil for the treatment of sexual dysfunction in women.26,27 While sil-denafil is currently not FDA-approved for this indication, clinical trials have shown improvement of sexual function for some women.

Additional studies are necessary to establish clinical efficacy in a larger patient population and to define which female patients may receive benefit from treatment with sildenafil.

How Does Cialis Work for Women?

Tadalafil has a longer time to maximum concentration and a longer half-life compared to sildenafil and vardenafil. This may allow greater spontaneity and less frequent dosing of tadalafil but may also prolong adverse effects. Additionally, tadalafil and vardenafil have greater selectivity for PDE-5 than sildenafil; this may produce a lower incidence of ocular adverse effects. These differences will need to be substantiated in post-marketing surveillance to provide evidence of their clinical significance. When selecting the most suitable PDE-5 inhibitor for a patient, sildenafil has the greatest amount of data supporting its efficacy and safety long-term and will most likely remain the drug of choice until more long-term data are available for the other agents.

Publisher’s Note

Sildenafil, vardenafil, and tadalafil are currently not on the Cleveland Clinic Foundation Formulary of Accepted Drugs. Erectile dysfunction in the elderly: epidemiology, etiology, and approaches to treatment. Tadalafil: an oral selective phosphodiesterase 5 inhibitor for treatment of erectile dysfunction. National Institutes of Health consensus development panel on impotence. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Sildenafil, vardenafil, and tadalafil are all effective treatments for ED by inhibiting PDE-5. Some differences exist that may clinically differentiate these agents. Tadalafil has a longer time to maximum concentration and a longer half-life compared to sildenafil and vardenafil. This may allow greater spontaneity and less frequent dosing of tadalafil but may also prolong adverse effects.

Does Cialis (tadalafil) work for women?

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Briggs GG, Freeman RK, Yaffe SJ, editors. A reference guide to fetal and neonatal risk: drugs in pregnancy and lactation 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p.

Does tadalafil improve endothelial function for better workouts?

v11-xxiv. Sildenafil for iatrogenic serotonergic antidepressant medication-induced sexual dysfunction in 4 patients. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BZ371A 2.5 mg (0.5 ml) BZ371A 7.5 mg (1.5 ml) Women between the ages 21 and 60; Women between the ages 21 and 60; Pre-menopausal or post-menopausal women may be included; Pre-menopausal or post-menopausal women may be included; May or may not be taking female sex hormones (estrogen with or without progesterone,or their derivatives); May or may not be taking female sex hormones (estrogen with or without progesterone,or their derivatives); FSAD, defined as the inability, persistent or recurrent, to obtain or maintain untilthe conclusion of sexual activity an adequate genital response to sexual arousal (lubrication, warmth and enlargement of the clitoris); FSAD, defined as the inability, persistent or recurrent, to obtain or maintain untilthe conclusion of sexual activity an adequate genital response to sexual arousal (lubrication, warmth and enlargement of the clitoris); Women with FSAD who present marked suffering or interpersonal difficulties; Women with FSAD who present marked suffering or interpersonal difficulties; Stable relationship for more than 6 months, with a sexually active partner; Stable relationship for more than 6 months, with a sexually active partner; Ability to read and understand the Informed Consent Form (ICF) and to answer thequestionnaires. Additionally, tadalafil and vardenafil have greater selectivity for PDE-5 than sildenafil; this may produce a lower incidence of ocular adverse effects. These differences will need to be substantiated in post-marketing surveillance to provide evidence of their clinical significance.

What are the potential benefits of tadalafil for women?

Selection of patients

When selecting the most suitable PDE-5 inhibitor for a patient, sildenafil has the greatest amount of data supporting its efficacy and safety long-term and will most likely remain the drug of choice until more long-term data are available for the other agents. Sildenafil, vardenafil, and tadalafil are currently not on the Cleveland Clinic Foundation Formulary of Accepted Drugs. Erectile dysfunction in the elderly: epidemiology, etiology, and approaches to treatment. Tadalafil: an oral selective phosphodiesterase 5 inhibitor for treatment of erectile dysfunction. National Institutes of Health consensus development panel on impotence. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. West Haven, CT: Bayer Pharmaceuticals Corporation; 2003 August. Indianapolis, IN: Eli Lilly and Corporation; 2003 November. Eardley I, Carteledge J. Tadalafil (Cialis™) for men with erectile dysfunction.

• Tadalafil belongs to PDE5 inhibitors, aiding blood flow.
• It is sometimes called "female Viagra" in popular media.
• Tadalafil's duration of action is approximately 36 hours.
• Female users should consult healthcare providers before use.
• Tadalafil may interact with other medications like nitrates.
• Existing studies show mixed results on tadalafil’s efficacy in women.
• It may be more effective when combined with therapy.
• Not recommended for women with certain cardiovascular conditions.
• Female use of tadalafil is still experimental and investigational.

de Tejada IS, Anglin G, Knight JR, Emmick JT. Effects of tadalafil erectile dysfunction pills tadalafil on erectile dysfunction in men with diabetes. Jackson G, Betteridge J, Dean J, Eardley I, Hall R, Holdright D, et al. A systematic approach to erectile dysfunction in the cardiovascular patient: a consensus statement-update 2002. Efficacy and safety of tadalafil for the treatment of erectile dysfunction:results of integrated analyses. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R.

What is tadalafil?

Ability to read and understand the Informed Consent Form (ICF) and to answer thequestionnaires. Women who do not agree to use a contraceptive method and who have the capacity tobecome pregnant during the study; Women who do not agree to use a contraceptive method and who have the capacity tobecome pregnant during the study; Women who do not agree to attempt sexual activity at least twice a week while takingthe study medication; Women who do not agree to attempt sexual activity at least twice a week while takingthe study medication; History of unresolved sexual trauma or abuse; History of unresolved sexual trauma or abuse; Diagnosis of vaginismus, genitopelvic pain/penetration disorder and/or sexualaversion disorder; Diagnosis of vaginismus, genitopelvic pain/penetration disorder and/or sexualaversion disorder; Uncontrolled diabetes at screening visit (HbA1C > 10%); Uncontrolled diabetes at screening visit (HbA1C > 10%); Prior spinal cord injury, with lower limb paralysis; Prior spinal cord injury, with lower limb paralysis; History of abdominal or pelvic surgery that may have damaged pelvic nerves,including vulvectomy, colostomy, cytostomy, hysterectomy, or bladder suspension. History of abdominal or pelvic surgery that may have damaged pelvic nerves,including vulvectomy, colostomy, cytostomy, hysterectomy, or bladder suspension. Current testosterone use, or long-term testosterone use (such as chip) within thepast 6 months; Current testosterone use, or long-term testosterone use (such as chip) within thepast 6 months; Presence of menstrual irregularity or endocrinopathies that significantly alter themenstrual cycle, preventing Cytocam analyses from taking place at the same time; Presence of menstrual irregularity or endocrinopathies that significantly alter themenstrual cycle, preventing Cytocam analyses from taking place at the same time; Patients with current depression, characterized by the use or need for use ofpsychotropic drugs, including bupropion, lithium, or neuroleptics; Patients with current depression, characterized by the use or need for use ofpsychotropic drugs, including bupropion, lithium, or neuroleptics; Presence of genital lesions that impair analysis of local adverse effects on thegenitalia; Presence of genital lesions that impair analysis of local adverse effects on thegenitalia; Presence of diseases that cause excessive vaginal discharge, such as recurrenturinary tract infection, vaginal infection and pelvic inflammatory disease. Presence of diseases that cause excessive vaginal discharge, such as recurrenturinary tract infection, vaginal infection and pelvic inflammatory disease.

Table 4.

Abnormal Papanicolaou test within the past 3 years; Abnormal Papanicolaou test within the past 3 years; History of gynecological cancer (history of uterine dysplasia can be included,provided it has been properly treated for at least 6 months); History of gynecological cancer (history of uterine dysplasia can be included,provided it has been properly treated for at least 6 months); Use of topical medications in the genital region that may interfere with PSIassessment as well as their absorption or drug interaction, including vaginalestrogens, lubricants, spermicides, creams or gels, vaginal douches; Use of topical medications in the genital region that may interfere with PSIassessment as well as their absorption or drug interaction, including vaginalestrogens, lubricants, spermicides, creams or gels, vaginal douches; History of symptomatic hypotension, or diseases that increase the risk ofsymptomatic hypotension, such as patient with heart disease (including history ofangina and/or heart failure) and nephropathies; History of symptomatic hypotension, or diseases that increase the risk ofsymptomatic hypotension, such as patient with heart disease (including history ofangina and/or heart failure) and nephropathies; Current use of nitrates, such as propatylnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®,Nitronal®, Tridil®) and sosorbitol dinitrate (Isocord®) Current use of nitrates, such as propatylnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®,Nitronal®, Tridil®) and sosorbitol dinitrate (Isocord®) ECG findings that are clinically symptomatic, or that, in the Investigator'sjudgment, are considered significant and pose a risk to the research volunteer'sparticipation; ECG findings that are clinically symptomatic, or that, in the Investigator'sjudgment, are considered significant and pose a risk to the research volunteer'sparticipation; Findings on laboratory tests that, in the Investigator's judgment, are consideredsignificant and offer risk to the research volunteer's participation or may hinderthe study analyses; Findings on laboratory tests that, in the Investigator's judgment, are consideredsignificant and offer risk to the research volunteer's participation or may hinderthe study analyses; TSH outside normal limits for age (participants with hypothyroidism on stable doseof medication, over 3 months, may be included); TSH outside normal limits for age (participants with hypothyroidism on stable doseof medication, over 3 months, may be included); BP outside safe limits: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg orabove 100 mmHg, except for situations such as "white coat" syndrome BP outside safe limits: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg orabove 100 mmHg, except for situations such as "white coat" syndrome Severe hypertension, considered as use of three or more antihypertensives; Severe hypertension, considered as use of three or more antihypertensives; Diseases that can cause clitoral priapism, such as sickle cell anemia, multiplemyeloma or leukemia; Diseases that can cause clitoral priapism, such as sickle cell anemia, multiplemyeloma or leukemia; Current relevant diarrhea, defined as duration over four weeks, association withabdominal pain or malabsorptive syndrome, or presence of mucus, pus, or blood in thestool; Current relevant diarrhea, defined as duration over four weeks, association withabdominal pain or malabsorptive syndrome, or presence of mucus, pus, or blood in thestool; Current use of nitric oxide donors, guanylate cyclase stimulators (e.g. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Briggs GG, Freeman RK, Yaffe SJ, editors. A reference guide to fetal and neonatal risk: drugs in pregnancy and lactation 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.

• Tadalafil has been studied for use in women with diabetic sexual dysfunction.
• Some reports suggest improved functionality with daily use.
• It is being evaluated for postpartum sexual health issues.
• Female-specific studies include subjective sexual satisfaction assessments.
• Tadalafil's use in women remains an off-label option.
• Side effects in women tend to be mild but should be monitored.
• It may benefit women experiencing vaginal dryness due to blood flow issues.
• Weekly or as-needed dosing strategies are under investigation.
• Women interested should seek specialized medical advice.

p. v11-xxiv.

Sildenafil for iatrogenic serotonergic antidepressant medication-induced sexual dysfunction in 4 patients.

Combining Therapies: Tadalafil, Oxytocin, and Bremelanotide (PT-141)

West Haven, CT: Bayer Pharmaceuticals Corporation; 2003 August. Indianapolis, IN: Eli Lilly and Corporation; 2003 November. Eardley I, Carteledge J. Tadalafil (Cialis™) for men with erectile dysfunction. de Tejada IS, Anglin G, Knight JR, Emmick JT.

Tadalafil and insulin sensitivity: why it matters for muscle gain

Effects of tadalafil erectile dysfunction pills tadalafil on erectile dysfunction in men with diabetes. Jackson G, Betteridge J, Dean J, Eardley I, Hall R, Holdright D, et al. A systematic approach to erectile dysfunction in the cardiovascular patient: a consensus statement-update 2002. Efficacy and safety of tadalafil for the treatment of erectile dysfunction:results of integrated analyses. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BZ371A 2.5 mg (0.5 ml) BZ371A 7.5 mg (1.5 ml) Women between the ages 21 and 60; Women between the ages 21 and 60; Pre-menopausal or post-menopausal women may be included; Pre-menopausal or post-menopausal women may be included; May or may not be taking female sex hormones (estrogen with or without progesterone,or their derivatives); May or may not be taking female sex hormones (estrogen with or without progesterone,or their derivatives); FSAD, defined as the inability, persistent or recurrent, to obtain or maintain untilthe conclusion of sexual activity an adequate genital response to sexual arousal (lubrication, warmth and enlargement of the clitoris); FSAD, defined as the inability, persistent or recurrent, to obtain or maintain untilthe conclusion of sexual activity an adequate genital response to sexual arousal (lubrication, warmth and enlargement of the clitoris); Women with FSAD who present marked suffering or interpersonal difficulties; Women with FSAD who present marked suffering or interpersonal difficulties; Stable relationship for more than 6 months, with a sexually active partner; Stable relationship for more than 6 months, with a sexually active partner; Ability to read and understand the Informed Consent Form (ICF) and to answer thequestionnaires. Ability to read and understand the Informed Consent Form (ICF) and to answer thequestionnaires. Women who do not agree to use a contraceptive method and who have the capacity tobecome pregnant during the study; Women who do not agree to use a contraceptive method and who have the capacity tobecome pregnant during the study; Women who do not agree to attempt sexual activity at least twice a week while takingthe study medication; Women who do not agree to attempt sexual activity at least twice a week while takingthe study medication; History of unresolved sexual trauma or abuse; History of unresolved sexual trauma or abuse; Diagnosis of vaginismus, genitopelvic pain/penetration disorder and/or sexualaversion disorder; Diagnosis of vaginismus, genitopelvic pain/penetration disorder and/or sexualaversion disorder; Uncontrolled diabetes at screening visit (HbA1C > 10%); Uncontrolled diabetes at screening visit (HbA1C > 10%); Prior spinal cord injury, with lower limb paralysis; Prior spinal cord injury, with lower limb paralysis; History of abdominal or pelvic surgery that may have damaged pelvic nerves,including vulvectomy, colostomy, cytostomy, hysterectomy, or bladder suspension. History of abdominal or pelvic surgery that may have damaged pelvic nerves,including vulvectomy, colostomy, cytostomy, hysterectomy, or bladder suspension. Current testosterone use, or long-term testosterone use (such as chip) within thepast 6 months; Current testosterone use, or long-term testosterone use (such as chip) within thepast 6 months; Presence of menstrual irregularity or endocrinopathies that significantly alter themenstrual cycle, preventing Cytocam analyses from taking place at the same time; Presence of menstrual irregularity or endocrinopathies that significantly alter themenstrual cycle, preventing Cytocam analyses from taking place at the same time; Patients with current depression, characterized by the use or need for use ofpsychotropic drugs, including bupropion, lithium, or neuroleptics; Patients with current depression, characterized by the use or need for use ofpsychotropic drugs, including bupropion, lithium, or neuroleptics; Presence of genital lesions that impair analysis of local adverse effects on thegenitalia; Presence of genital lesions that impair analysis of local adverse effects on thegenitalia; Presence of diseases that cause excessive vaginal discharge, such as recurrenturinary tract infection, vaginal infection and pelvic inflammatory disease. Presence of diseases that cause excessive vaginal discharge, such as recurrenturinary tract infection, vaginal infection and pelvic inflammatory disease.

Abnormal Papanicolaou test within the past 3 years; Abnormal Papanicolaou test within the past 3 years; History of gynecological cancer (history of uterine dysplasia can be included,provided it has been properly treated for at least 6 months); History of gynecological cancer (history of uterine dysplasia can be included,provided it has been properly treated for at least 6 months); Use of topical medications in the genital region that may interfere with PSIassessment as well as their absorption or drug interaction, including vaginalestrogens, lubricants, spermicides, creams or gels, vaginal douches; Use of topical medications in the genital region that may interfere with PSIassessment as well as their absorption or drug interaction, including vaginalestrogens, lubricants, spermicides, creams or gels, vaginal douches; History of symptomatic hypotension, or diseases that increase the risk ofsymptomatic hypotension, such as patient with heart disease (including history ofangina and/or heart failure) and nephropathies; History of symptomatic hypotension, or diseases that increase the risk ofsymptomatic hypotension, such as patient with heart disease (including history ofangina and/or heart failure) and nephropathies; Current use of nitrates, such as propatylnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®,Nitronal®, Tridil®) and sosorbitol dinitrate (Isocord®) Current use of nitrates, such as propatylnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®,Nitronal®, Tridil®) and sosorbitol dinitrate (Isocord®) ECG findings that are clinically symptomatic, or that, in the Investigator'sjudgment, are considered significant and pose a risk to the research volunteer'sparticipation; ECG findings that are clinically symptomatic, or that, in the Investigator'sjudgment, are considered significant and pose a risk to the research volunteer'sparticipation; Findings on laboratory tests that, in the Investigator's judgment, are consideredsignificant and offer risk to the research volunteer's participation or may hinderthe study analyses; Findings on laboratory tests that, in the Investigator's judgment, are consideredsignificant and offer risk to the research volunteer's participation or may hinderthe study analyses; TSH outside normal limits for age (participants with hypothyroidism on stable doseof medication, over 3 months, may be included); TSH outside normal limits for age (participants with hypothyroidism on stable doseof medication, over 3 months, may be included); BP outside safe limits: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg orabove 100 mmHg, except for situations such as "white coat" syndrome BP outside safe limits: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg orabove 100 mmHg, except for situations such as "white coat" syndrome Severe hypertension, considered as use of three or more antihypertensives; Severe hypertension, considered as use of three or more antihypertensives; Diseases that can cause clitoral priapism, such as sickle cell anemia, multiplemyeloma or leukemia; Diseases that can cause clitoral priapism, such as sickle cell anemia, multiplemyeloma or leukemia; Current relevant diarrhea, defined as duration over four weeks, association withabdominal pain or malabsorptive syndrome, or presence of mucus, pus, or blood in thestool; Current relevant diarrhea, defined as duration over four weeks, association withabdominal pain or malabsorptive syndrome, or presence of mucus, pus, or blood in thestool; Current use of nitric oxide donors, guanylate cyclase stimulators (e.g.